AFN-1252
Phase 2- Indications
- Staphylococcal infections, Methicillin-resistant Staphylococcus aureus (MRSA), Sepsis
Company intelligence / Profile preview
Affinium Pharmaceuticals
Austin, Texas, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
AFN-1252 successfully completed a Phase 2a study for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The compound demonstrated excellent efficacy, safety, and tolerability profile in over 250 subjects.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Debiopharm Group
Beyond the preview
Go deeper on Affinium Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affinium Pharmaceuticals.